For example, in lung adeno-carcinoma and glioblastoma multiforme (GBM) cells, it has been revealed that NMDAR antagonists inhibit the ERK1/2 and CREB pathways, respectively [19,23]. Here, MAPK3 is linked to glioblastoma.